Moreover, several randomized controlled trials have tested either naked plasmids or adenoviral vectors to deliver VEGF for the treatment of severe coronary heart diseases, such as EuroinjectOne, KAT, REVASC, NOTHERN, NOVA, and VEGF-Neupogen [297,298,299,300,301,302]. Here, VEGFA is linked to coronary artery disorder.